Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Economics Weekly: A Look Ahead at the 2026 Midterms

    In this Economics Weekly, we examine the key issues shaping voters’ views as the November midterm elections approach, assess which parties are most likely to control the House and Senate, and consider the potential ramifications for the remainder of the Trump presidency.

    Read more

  • The Evolution of In Vivo CAR-T Therapies

    In vivo CAR-T Therapies are accelerating fast and offering rapid, lab-free treatments powered by viral and LNP breakthroughs. Early clinical wins and rising investment suggest these therapies could make advanced cell treatment far more accessible.

    Read more

  • 14 William Blair Women Wealth Advisors Named Best-in-State by Forbes

    "We’re incredibly proud to celebrate the growing number of William Blair women wealth advisors recognized on Forbes’ list,” said Ryan DeVore, head of William Blair Private Wealth Management.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures